Hepatorenal Syndrome

Hepatorenal syndrome is a devastating, life-threatening form of acute kidney injury that develops exclusively in patients with severe liver disease — most commonly decompensated cirrhosis with ascites. What makes HRS uniquely cruel is that the kidneys themselves are structurally normal; the kidney failure is driven entirely by functional circulatory collapse, not by any intrinsic kidney pathology. When a liver transplant restores normal hepatic function, the kidneys recover completely — proving that the kidney is an innocent bystander to liver-driven hemodynamic catastrophe.

Table of Contents

  1. What is Hepatorenal Syndrome?
  2. Pathophysiology: The Circulatory Collapse Behind HRS
  3. HRS-AKI vs HRS-CKD: The 2015 ICA Classification
  4. Triggers and Precipitants
  5. Diagnosis: The Updated ICA 2015 Criteria
  6. Terlipressin: The Key Vasoconstrictor Treatment
  7. Albumin Infusion and the Role of Volume Expansion
  8. Norepinephrine and Octreotide/Midodrine Alternatives
  9. Liver Transplantation: The Only Cure
  10. Renal Replacement Therapy and Prognosis
  11. Research Papers
  12. Connections
  13. Featured Videos

What is Hepatorenal Syndrome?

Hepatorenal syndrome (HRS) is a form of acute kidney injury that develops in patients with severe liver disease — most commonly decompensated cirrhosis accompanied by ascites, but also in acute liver failure (ALF) and severe alcoholic hepatitis. The defining and most clinically important feature is that the kidneys themselves are structurally and histologically normal. There is no glomerulonephritis, no tubular necrosis, no obstructive uropathy — just a kidney that has been functionally shut down by the systemic hemodynamic chaos created by a failing liver.

The most compelling proof of this is what happens after liver transplantation: once normal hepatic function is restored, renal perfusion normalizes and kidney function recovers completely. The kidney was never broken — it was simply starved of blood flow by events originating entirely in the liver. This functional origin distinguishes HRS from virtually every other form of renal failure and explains why treatment must target the liver's hemodynamic consequences rather than the kidney itself.

HRS presents in two broad patterns. HRS-AKI (formerly called Type 1 HRS) is the rapidly progressive form: serum creatinine often doubles within two weeks, and without treatment the median survival is approximately two weeks. It is typically precipitated by a specific trigger — an infection, a bleed, or a large-volume paracentesis without adequate albumin replacement. HRS-CKD (formerly Type 2 HRS) is more gradual, develops over months, and is typically seen in the context of refractory ascites. Median survival is three to six months without transplantation.

The incidence of HRS is sobering: approximately 40% of patients with cirrhosis and ascites develop some form of HRS within five years of their cirrhosis diagnosis. Even with the best available vasoconstrictor therapy, short-term mortality remains high. HRS illustrates, more starkly than almost any other syndrome, how inseparably linked the liver and kidney are — the "hepatorenal" name is not just descriptive anatomy but a statement about the interconnected fate of both organs in the setting of advanced liver disease.

Back to Table of Contents

Pathophysiology: The Circulatory Collapse Behind HRS

The central mechanism driving hepatorenal syndrome is a progressive, self-amplifying cycle of splanchnic vasodilation and renal vasoconstriction — a physiological paradox in which the body's own attempts to compensate for falling blood pressure ultimately destroy kidney function.

It begins with portal hypertension. In advanced cirrhosis, elevated portal venous pressure triggers the release of vasodilatory mediators — most critically nitric oxide (NO), but also carbon monoxide, prostacyclin, and endocannabinoids — into the splanchnic circulation. The mesenteric arterioles respond by dilating dramatically. This splanchnic vasodilation has an important consequence: blood pools in the gut's capillary beds, reducing the volume of blood returning to the central circulation. The effective arterial blood volume falls — even as the total body water is actually expanded (the patient has ascites, peripheral edema, and dilutional hyponatremia).

Baroreceptors in the aortic arch and carotid bodies sense this drop in effective circulating volume and trigger three compensatory vasoconstrictor systems simultaneously: the renin-angiotensin-aldosterone system (RAAS), which increases angiotensin II; the sympathetic nervous system (SNS), which releases norepinephrine; and antidiuretic hormone (ADH/vasopressin), which causes renal water retention and vasoconstriction. These systems succeed in raising systemic vascular resistance enough to maintain a marginal blood pressure — but they do so partly by constricting the renal afferent arterioles, reducing glomerular filtration pressure and causing AKI. The treatment that is killing the patient is the body's own vasoconstrictor response.

A second major driver is bacterial translocation. In advanced cirrhosis, the gut epithelial barrier is damaged and intestinal motility is impaired, allowing bacteria and bacterial endotoxins (particularly lipopolysaccharide) to cross from the gut lumen into mesenteric lymph nodes and then into the systemic circulation. This systemic bacterial translocation activates pattern recognition receptors (Toll-like receptors), triggering a chronic inflammatory state that further stimulates nitric oxide synthase in the splanchnic vasculature, worsening the vasodilation. Simultaneously, the damaged liver cannot clear vasoactive substances — including endothelin, leukotrienes, and thromboxane — that would normally be metabolized by hepatic Kupffer cells, compounding the hemodynamic instability.

The net result is kidneys that receive markedly reduced perfusion despite a body that is volume-overloaded. The renal cortex is relatively ischemic while the rest of the body is edematous. This is why fluid alone cannot reverse HRS — you cannot fix a vasoconstriction problem with volume alone. The fundamental problem is splanchnic vasodilation, and correcting it requires vasoconstrictors targeted at the splanchnic bed.

Back to Table of Contents

HRS-AKI vs HRS-CKD: The 2015 ICA Classification

The historical "Type 1" and "Type 2" HRS terminology was replaced in 2015 by the International Club of Ascites (ICA) with a classification system that integrates HRS into the broader framework of acute kidney injury definitions. This change reflects growing recognition that the old binary types did not capture the full clinical spectrum and that HRS-AKI is better understood in the context of the AKI staging system used for all critically ill patients.

HRS-AKI (Formerly Type 1 HRS)

HRS-AKI is defined by a rapid deterioration in kidney function meeting AKI criteria: serum creatinine rise of 0.3 mg/dL or more within 48 hours, OR a rise of 1.5 times or more above baseline within 7 days, OR urine output below 0.5 mL/kg/h for 6 or more hours. Creatinine in HRS-AKI often exceeds 2.5 mg/dL and may rise to 5–7 mg/dL without treatment. Median survival without treatment is approximately two weeks. A precipitating event — infection, GI bleeding, large-volume paracentesis without albumin — is identifiable in most cases.

AKI in cirrhosis is further staged by the ICA: Stage 1 = creatinine rise of 0.3 mg/dL or more, or 1.5–2 times baseline; Stage 2 = 2–3 times baseline; Stage 3 = more than 3 times baseline, above 4.0 mg/dL, or requiring renal replacement therapy. HRS-AKI typically presents at Stage 2 or 3.

HRS-CKD (Formerly Type 2 HRS)

HRS-CKD is defined by an estimated glomerular filtration rate below 60 mL/min/1.73m² for more than 3 months in a patient with cirrhosis, in the absence of an identifiable structural kidney cause. It is more gradual in onset and is clinically characterized by refractory ascites — ascites that cannot be controlled by diuretics alone and requires repeated large-volume paracentesis. Median survival is 3–6 months without liver transplantation. Treatment with vasoconstrictors is less well-defined in HRS-CKD than in HRS-AKI, and the evidence base for terlipressin is primarily derived from HRS-AKI trials.

An important practical point: some patients with HRS-CKD develop a superimposed episode of HRS-AKI after a precipitating event — this carries the worst prognosis of all HRS presentations, since they have neither the hemodynamic reserve of a patient with previously normal kidney function nor the time course that allows gradual compensation.

Back to Table of Contents

Triggers and Precipitants

Hepatorenal syndrome almost never develops spontaneously in a patient with stable cirrhosis. In the vast majority of cases, there is an identifiable precipitating event that tips the already-precarious hemodynamic balance over into functional renal failure. Recognizing and preventing these triggers is one of the most effective strategies for reducing HRS incidence.

Spontaneous Bacterial Peritonitis (SBP)

SBP is the single most common precipitant of HRS-AKI, accounting for approximately one-third of cases. HRS develops in 30% of SBP episodes when albumin infusion is not given alongside antibiotics — a rate that drops to approximately 10% when albumin is administered. The mechanism is that SBP triggers a massive systemic inflammatory response that further amplifies splanchnic vasodilation and worsens renal perfusion. The landmark Sort et al. trial (NEJM 1999) established albumin infusion at 1.5 g/kg on day 1 and 1 g/kg on day 3 of SBP treatment as the standard of care to prevent HRS.

Large-Volume Paracentesis Without Albumin Replacement

Removing more than 5 liters of ascites without replacing albumin causes paracentesis-induced circulatory dysfunction (PICD): the sudden reduction in intraperitoneal pressure causes splanchnic arteries to dilate further as the mechanical support of the tense ascites is removed. The standard of care is albumin replacement at 6–8 g per liter of ascites removed for paracentesis volumes exceeding 5 liters.

Gastrointestinal Bleeding

Variceal or non-variceal GI bleeding causes two compounding insults: acute hypovolemia from blood loss, and bacterial translocation from gut ischemia and disrupted mucosal integrity. Both worsen effective arterial blood volume and trigger the vasoconstrictor cascade. Antibiotic prophylaxis (norfloxacin or ceftriaxone) during acute variceal bleeding has been shown to reduce not only bacterial infections but also the incidence of HRS and mortality.

Infection Beyond SBP

Any bacterial infection — urinary tract infection, pneumonia, cellulitis, bacteremia — can precipitate HRS by the same inflammatory mechanism as SBP, albeit typically with less severity. Empirical antibiotics should be started promptly when infection is suspected in a cirrhotic patient, and renal function should be monitored closely during and after treatment.

Nephrotoxic Medications

NSAIDs are particularly dangerous in cirrhosis and are considered absolutely contraindicated. In cirrhosis, renal prostaglandins (prostaglandin E2 and prostacyclin) provide a crucial counter-regulatory vasodilatory effect on the renal vasculature that partially offsets the RAAS/SNS-driven vasoconstriction. NSAIDs inhibit this prostaglandin synthesis, removing the last defense of renal perfusion and precipitating abrupt AKI. Aminoglycosides and iodinated contrast agents also carry significantly elevated nephrotoxicity risk in cirrhosis and should be avoided or used with extreme caution and careful hydration.

Over-Diuresis

Overly aggressive diuresis with furosemide and spironolactone — the standard medications for ascites management — can cause intravascular volume depletion that precipitates pre-renal AKI that progresses to HRS. Serum creatinine and electrolytes must be monitored closely during diuretic titration; diuretics should be held when creatinine begins to rise.

Prevention Strategy

Primary prophylaxis with norfloxacin 400 mg daily (or rifaximin in patients intolerant of norfloxacin) is recommended for high-risk patients — those with prior SBP, low ascitic fluid protein (<1.5 g/dL) plus renal impairment or hyponatremia, or Child-Pugh score C cirrhosis — to reduce bacterial translocation and lower HRS risk. Avoid NSAIDs universally in cirrhosis. Monitor renal function at every clinical encounter in patients with decompensated cirrhosis.

Back to Table of Contents

Diagnosis: The Updated ICA 2015 Criteria

HRS-AKI is a diagnosis of exclusion. Before labeling a cirrhotic patient's deteriorating kidney function as HRS, the clinician must systematically exclude other, more treatable causes of AKI. The ICA 2015 criteria formalize this process into a stepwise evaluation.

ICA 2015 Diagnostic Criteria for HRS-AKI

  1. Cirrhosis with ascites (or acute liver failure or alcoholic hepatitis).
  2. AKI diagnosis present: serum creatinine rise of 0.3 mg/dL or more within 48 hours, or 1.5 times or more above baseline within 7 days, or urine output below 0.5 mL/kg/h for 6 hours or more.
  3. No improvement after 48 hours of diuretic withdrawal AND volume expansion with albumin 1 g/kg/day (maximum 100 g/day). This albumin challenge is both diagnostic (if creatinine improves, the AKI was pre-renal or albumin-responsive) and the first step of treatment (if creatinine fails to improve, HRS-AKI is confirmed and vasoconstrictors are initiated).
  4. Absence of shock: septic, hypovolemic, or cardiogenic shock must be excluded — these have their own treatments and produce AKI by different mechanisms.
  5. No current or recent use of nephrotoxic medications: NSAIDs, aminoglycosides, contrast agents.
  6. No macroscopic signs of structural kidney disease: no proteinuria above 500 mg/day (suggesting glomerulonephritis), no microhematuria above 50 red blood cells per high-power field, and a normal kidney ultrasound (excluding obstruction, polycystic disease, or parenchymal disease).

Key Laboratory Clues

The urinalysis in HRS-AKI is characteristically bland: virtually no cellular casts, minimal proteinuria, very few red or white blood cells. This "quiet" urinary sediment in the context of rising creatinine is a strong pointer toward functional AKI rather than intrinsic renal disease. Urine sodium is typically extremely low — below 10 mEq/L — reflecting the kidneys' desperate attempt to conserve sodium under RAAS/SNS drive. Fractional excretion of sodium (FENa) is below 1%, and fractional excretion of urea (FEUrea) below 35%. These findings mirror pre-renal AKI, which is why the albumin challenge is essential — it distinguishes pre-renal AKI (which responds) from HRS-AKI (which does not).

Kidney biopsy is not routinely required to diagnose HRS and is rarely performed acutely in cirrhotic patients (who often have coagulopathy), but when it has been performed in research settings, the histology is strikingly normal — minimal or no glomerular, tubular, or interstitial changes. This confirms the purely functional nature of the renal failure.

Contrast-enhanced CT scanning is generally avoided in suspected HRS due to the nephrotoxicity of iodinated contrast in an already-vulnerable kidney. Ultrasound is the preferred imaging modality to exclude obstruction and assess for intrinsic structural disease.

Back to Table of Contents

Terlipressin: The Key Vasoconstrictor Treatment

Terlipressin (brand name Terlivaz in the US) is the pivotal pharmacological treatment for HRS-AKI. A synthetic vasopressin analogue with selective agonism at V1 receptors on splanchnic arteriolar smooth muscle, terlipressin was approved by the FDA in January 2022 — making it the first FDA-approved treatment specifically for HRS-AKI. It had been used in Europe and Asia for over two decades before US approval.

Mechanism of Action

Terlipressin causes splanchnic vasoconstriction by activating V1 vasopressin receptors on the smooth muscle of mesenteric and other splanchnic arterioles. By constricting these vessels, it directly counteracts the pathological splanchnic vasodilation that drives HRS. As splanchnic vascular tone increases, blood is redistributed away from the gut's capillary beds and back toward the central circulation, increasing effective arterial blood volume. This reduces baroreceptor activation of RAAS, SNS, and ADH, lowering the vasoconstrictor drive on the renal vasculature and allowing glomerular perfusion pressure to recover.

Dosing and Administration

Terlipressin is given intravenously: starting dose 1 mg every 4–6 hours, which can be increased to 2 mg every 4 hours if creatinine fails to fall by at least 25% within 48 hours. Treatment duration is up to 14 days or until a complete response is achieved. It is always administered alongside albumin infusion — the two work synergistically, with terlipressin correcting vasoconstriction and albumin expanding effective intravascular volume and providing anti-inflammatory benefit.

Evidence: The CONFIRM Trial

The pivotal CONFIRM trial (Wong et al., NEJM 2021; PMID 33626145) enrolled 300 patients with HRS-AKI at 60 sites in North America. Terlipressin achieved reversal of HRS-AKI — defined as two consecutive creatinine readings below 1.5 mg/dL — in 32% of patients vs 17% with placebo (p < 0.001). Overall 30-day survival was not significantly different between groups in the full population, though prespecified subgroup analyses showed survival benefit in patients with MELD scores of 35 or less at baseline. Critically, terlipressin was associated with a higher rate of respiratory failure, particularly in patients with baseline SpO2 below 90% or pre-existing hypoxia.

Contraindications and Cautions

Terlipressin is contraindicated in patients with respiratory failure or SpO2 below 90% at baseline — the CONFIRM trial demonstrated that these patients had significantly higher mortality with terlipressin than with placebo. Other contraindications include severe cardiovascular disease (coronary artery disease, peripheral arterial disease), acute mesenteric ischemia, and pregnancy. Side effects include abdominal cramping, diarrhea, hyponatremia (dilutional), coronary artery vasospasm, intestinal ischemia, and peripheral cyanosis. Patients on terlipressin require close monitoring in a hospital setting with pulse oximetry, cardiac monitoring, and serial creatinine measurements every 24–48 hours.

A complete response — creatinine falling below 1.5 mg/dL — predicts substantially better outcomes, including higher rates of successful bridge to liver transplantation and better 90-day survival. Patients who do not show at least a 25% creatinine reduction within 3 days of treatment are unlikely to achieve a complete response and should be considered for alternative strategies or transplant listing escalation.

Back to Table of Contents

Albumin Infusion and the Role of Volume Expansion

Albumin occupies a unique position in HRS management: it is simultaneously a diagnostic tool (the albumin challenge to exclude pre-renal AKI) and a treatment adjunct (given alongside vasoconstrictors to support circulating volume and reduce inflammation). No vasoconstrictor regimen for HRS is given without concomitant albumin infusion.

Mechanisms of Benefit

Albumin's effects in HRS extend well beyond simple oncotic pressure support. Three mechanisms are clinically relevant: (1) Oncotic effect: albumin's large molecular size and negative charge draw fluid from the interstitium and ascites back into the intravascular compartment, transiently expanding effective circulating volume and reducing the baroreceptor-mediated vasoconstrictor drive on the kidney. (2) Anti-inflammatory effects: albumin binds and neutralizes lipopolysaccharide (endotoxin) from bacterial translocation, reducing the inflammatory stimulus for splanchnic vasodilation and nitric oxide production. (3) Antioxidant and scavenging properties: albumin contains a free thiol group (Cys-34) that scavenges reactive oxygen species and prevents lipid peroxidation, providing cytoprotective effects on the renal tubular epithelium. In cirrhosis, the albumin molecule itself is often oxidized and structurally dysfunctional — this "non-oncotic" dysfunction may explain why some cirrhotic patients respond poorly to albumin infusions despite normal serum albumin levels.

Dosing Regimens

For the diagnostic albumin challenge to exclude pre-renal AKI: albumin 1 g/kg/day (up to 100 g/day) for two days; if creatinine fails to improve, HRS-AKI is diagnosed and vasoconstrictor therapy is started. For treatment alongside terlipressin or norepinephrine: 1 g/kg loading dose followed by 20–40 g/day for the duration of treatment. For SBP prevention of HRS (the Sort protocol): 1.5 g/kg on day 1 of antibiotic treatment and 1 g/kg on day 3; this simple intervention reduces HRS incidence from approximately 33% to 10% in SBP episodes.

Only human albumin solutions (4–5% or 20–25% preparations) are appropriate in this setting. Artificial colloids — hydroxyethyl starch (HES) solutions, gelatin, dextrans — have been shown to cause renal tubular injury in critically ill patients and are specifically harmful in cirrhosis. Saline alone does not provide the anti-inflammatory, oncotic, and antioxidant benefits of albumin and is insufficient as the volume expansion arm of HRS management.

Back to Table of Contents

Norepinephrine and Octreotide/Midodrine Alternatives

Prior to FDA approval of terlipressin in January 2022, US clinicians managed HRS-AKI without a licensed vasoconstrictor. Two alternative regimens developed during that period remain important options — particularly for patients in whom terlipressin is contraindicated.

Norepinephrine

Norepinephrine is a potent alpha-1 and alpha-2 adrenergic agonist that causes systemic vasoconstriction, redistributing blood from the splanchnic bed toward the central and renal circulation. It is delivered by continuous intravenous infusion, titrated to achieve a mean arterial pressure (MAP) increase of at least 10 mmHg above baseline — a rise that correlates with renal perfusion improvement. Because norepinephrine requires continuous IV infusion and close hemodynamic monitoring, it is an ICU-based treatment only. Multiple retrospective and small randomized studies suggest efficacy comparable to terlipressin for HRS reversal, with some data suggesting fewer respiratory complications. A 2021 meta-analysis found similar rates of HRS reversal and 30-day mortality between norepinephrine and terlipressin. The practical advantage is cost (norepinephrine is inexpensive) and a potentially more favorable respiratory safety profile.

Octreotide and Midodrine

The octreotide-plus-midodrine combination was the dominant outpatient-capable alternative to terlipressin in the US before 2022. Octreotide is a somatostatin analogue that inhibits the release of splanchnic vasodilators (glucagon, substance P, VIP) from the gut, modestly reducing splanchnic vasodilation. Midodrine is an alpha-1 adrenergic agonist taken orally, producing systemic vasoconstriction. Used together, they provide complementary splanchnic and systemic vasoconstriction without requiring ICU monitoring. Typical dosing: midodrine 7.5–12.5 mg orally three times daily; octreotide 100–200 mcg subcutaneously three times daily; both combined with albumin infusion.

The Cavallin et al. randomized trial (Hepatology 2015; PMID 25644760) directly compared terlipressin-albumin vs. midodrine-octreotide-albumin in HRS-AKI: the terlipressin arm achieved complete response in 70% of patients vs. 29% in the midodrine-octreotide arm (p = 0.01). This trial established terlipressin as the preferred agent where available, while confirming midodrine-octreotide as a reasonable alternative when terlipressin is contraindicated or unavailable.

TIPS (Transjugular Intrahepatic Portosystemic Shunt)

TIPS reduces portal hypertension by creating a direct connection between the portal vein and a hepatic vein, bypassing the hepatic sinusoidal resistance. By lowering portal pressure, TIPS reduces the stimulus for splanchnic vasodilation and can improve renal perfusion. TIPS has demonstrated benefit for HRS-CKD and refractory ascites, with studies showing improvement in creatinine and reduced requirement for repeated paracentesis. However, TIPS carries significant risks in advanced liver disease: it can precipitate hepatic encephalopathy (by allowing portal blood to bypass hepatic metabolism) and is contraindicated in patients with poor hepatic reserve (bilirubin above 3–5 mg/dL, Child-Pugh C with severe decompensation). TIPS use for HRS-AKI is limited by the acuity of the syndrome and the technical constraints of performing the procedure in hemodynamically unstable patients.

Back to Table of Contents

Liver Transplantation: The Only Cure

All vasoconstrictor therapies for HRS are bridges — they aim to keep patients alive and maintain some residual kidney function until the only definitive treatment can be delivered: liver transplantation. Once a functioning liver is transplanted, the splanchnic vasodilation resolves, the vasoconstrictor cascade shuts down, and renal perfusion normalizes. Kidneys that had zero urine output in end-stage HRS begin to produce urine within hours of transplantation. This dramatic recovery is among the most compelling demonstrations of the functional (rather than structural) nature of HRS.

MELD Score and Transplant Prioritization

The MELD (Model for End-Stage Liver Disease) score — which incorporates serum creatinine, bilirubin, and INR — drives organ allocation in the US liver transplant system. Because HRS-AKI causes rapid creatinine elevation, it significantly raises the MELD score and therefore elevates the patient's urgency on the transplant waiting list. This is an intended feature of the system — patients with HRS have short expected survival without transplantation and are appropriately prioritized. However, the MELD score is capped at a maximum creatinine of 4.0 mg/dL, limiting how much HRS-driven creatinine rise can further increase MELD. MELD-Na (which incorporates serum sodium) provides additional prognostic discrimination, particularly for patients with HRS-associated dilutional hyponatremia.

Combined Liver-Kidney Transplantation (CLKT)

The question of whether a patient needs a liver transplant alone or a combined liver-kidney transplant (CLKT) is clinically important and sometimes difficult to answer under time pressure. Current guidance recommends CLKT when: (1) the patient has been on dialysis for 8 weeks or more; (2) there is evidence of underlying CKD with eGFR below 25 mL/min for more than 3 months prior to the acute decompensation; or (3) there is a known diagnosis of underlying chronic kidney disease (diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy) that would not be expected to recover after liver transplant alone. Patients who have developed HRS-AKI on a background of normal kidney function should generally receive liver transplant alone, as kidney recovery is expected.

Bridging Therapy and Outcomes

The goal of vasoconstrictor therapy is to maintain the patient in transplantable condition — alive, without uncontrolled infection, with sufficient residual kidney function to survive the transplant surgery and recovery period. Patients who achieve a complete response to terlipressin (creatinine falling below 1.5 mg/dL) before transplantation have outcomes after transplant that are similar to cirrhotic patients transplanted without HRS — suggesting that functional correction of HRS before transplant normalizes the surgical risk. Patients who proceed to transplant with ongoing HRS and on dialysis have higher post-transplant morbidity and longer hospital stays, though the majority still achieve good long-term outcomes if the new liver functions well. Active infection, severe cardiopulmonary disease, active alcohol use, and untreated extrahepatic malignancy are standard contraindications to transplantation.

Back to Table of Contents

Renal Replacement Therapy and Prognosis

Renal replacement therapy (RRT) — hemodialysis or continuous renal replacement therapy (CRRT) — plays a supportive role in HRS management. It does not treat the underlying cause of HRS (it cannot correct the hemodynamic abnormality driving renal failure), but it is essential for managing the life-threatening metabolic consequences while awaiting either response to vasoconstrictors or liver transplantation.

Indications and Modality

Standard indications for RRT in HRS-AKI are the same as in other causes of severe AKI: refractory hyperkalemia (potassium above 6.5 mEq/L despite medical management), severe metabolic acidosis (pH below 7.2), symptomatic uremia (encephalopathy, pericarditis), or volume overload causing respiratory failure. CRRT is generally preferred over intermittent hemodialysis in hemodynamically unstable patients — the continuous, gentle fluid and solute removal of CRRT is better tolerated than the rapid shifts of intermittent HD in patients with marginal blood pressure and splanchnic vasodilation. CRRT also avoids the hypotensive episodes during HD that can further compromise renal perfusion.

Prognosis Without Treatment

The natural history of untreated HRS-AKI is grim: median survival is approximately two weeks from the time of diagnosis without vasoconstrictor therapy. HRS-CKD carries a median survival of 3–6 months without transplantation. Even with the best available vasoconstrictor therapy, 30-day mortality in published trials ranges from 25–50% depending on disease severity. These sobering numbers underscore both the urgency of recognizing HRS early and the critical importance of liver transplant access.

Predictors of Non-Response to Vasoconstrictors

Several factors at the time of HRS-AKI diagnosis predict a poor response to terlipressin and identify patients who are unlikely to survive without urgent transplantation: MELD score above 35, serum bilirubin above 10 mg/dL, baseline creatinine above 3.5 mg/dL, absence of MAP rise within 48 hours of starting terlipressin, ACLF (acute-on-chronic liver failure) grade 3, and active or recent bacterial infection not yet controlled. Patients with ACLF grade 3 — defined by three or more organ failures — have near-100% 28-day mortality without transplantation regardless of vasoconstrictor treatment.

Future Directions

Research is ongoing across several fronts: liver support systems such as MARS (Molecular Adsorbent Recirculating System) and PROMETHEUS aim to provide artificial hepatic detoxification, potentially reducing the inflammatory and vasodilatory drive on the kidney. FXR (farnesoid X receptor) agonists are being studied to strengthen the gut epithelial barrier and reduce bacterial translocation — targeting the upstream trigger of splanchnic vasodilation. Longer-acting vasopressin analogues and novel nitric oxide synthase inhibitors are in early clinical trials. However, none of these approaches has yet demonstrated the survival benefit that liver transplantation provides, and transplantation remains the undisputed definitive therapy for HRS.

Back to Table of Contents

Research Papers

  1. Sort P, Naveau S, Gines P, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409. PMID: 10432325
  2. Wong F, Pappas SC, Curry MP, et al. (CONFIRM Trial). Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828. PMID: 33626145
  3. Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the ICA. J Hepatol. 2015;62(4):968–974. PMID: 25638527
  4. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin for hepatorenal syndrome type 1: a randomized controlled trial. Hepatology. 2015;62(2):567–574. PMID: 25644760
  5. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279–1290. PMID: 19776409
  6. Martín-Llahí M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352–1359. PMID: 18471512
  7. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28(2):416–422. PMID: 9695005
  8. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006;43(3):385–394. PMID: 16496305
  9. Rodriguez E, Elia C, Sola E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014;60(5):955–961. PMID: 24462139
  10. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839–1847. PMID: 12454841
  11. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–176. PMID: 8550036
  12. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in patients with advanced cirrhosis. Gut. 2007;56(9):1310–1318. PMID: 17389705

Back to Table of Contents

Connections

Back to Table of Contents